A
Anthony Sebba
Researcher at University of South Florida
Publications - 35
Citations - 2347
Anthony Sebba is an academic researcher from University of South Florida. The author has contributed to research in topics: Rheumatoid arthritis & Osteoporosis. The author has an hindex of 18, co-authored 33 publications receiving 2054 citations. Previous affiliations of Anthony Sebba include University of Santiago de Compostela & Genentech.
Papers
More filters
Journal ArticleDOI
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study
Graeme Jones,Anthony Sebba,Jieruo Gu,Mitchell B. Lowenstein,Armando Calvo,Juan J. Gomez-Reino,Daniel Siri,Matija Tomšič,Emma Alecock,Thasia G. Woodworth,Mark C. Genovese +10 more
TL;DR: Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit–risk, in patients for whom treatment with methotRexate or biological agents has not previously failed.
Journal ArticleDOI
Hydroxychloroquine concentration–response relationships in patients with rheumatoid arthritis
Tino Münster,John P. Gibbs,Danny D. Shen,Bruce A. Baethge,Gary R. Botstein,Jacques Caldwell,Fredrick Dietz,Robert E. Ettlinger,Harvey E. Golden,Herbert B. Lindsley,George E. Mclaughlin,Larry W. Moreland,W. Neal Roberts,Theodore W. Rooney,Bruce M. Rothschild,Marshall Sack,Anthony Sebba,Michael H. Weisman,Kathryn E. Welch,David E. Yocum,Daniel E. Furst,Daniel E. Furst +21 more
TL;DR: There is a weak, but predictable, relationship between blood DHCQ concentrations and efficacy of treatment with HCQ, and there is an association between gastrointestinal adverse events and elevated blood HCQ concentrations.
Journal ArticleDOI
Tocilizumab: the first interleukin-6-receptor inhibitor.
TL;DR: Tocilizumab, a novel IL-6R inhibitor, may be beneficial for the treatment of RA in patients who do not respond to methotrexate or disease-modifying antirheumatic drugs.
Journal ArticleDOI
Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years
Sydney Lou Bonnick,Kenneth G. Saag,Douglas P. Kiel,Michael R. McClung,Marc C. Hochberg,Sherri-Ann M. Burnett,Anthony Sebba,Risa Kagan,Erluo Chen,Desmond E. Thompson,Anne E. de Papp +10 more
TL;DR: A 1-yr extension of the Fosamax Actonel Comparison Trial was completed to compare changes in bone mineral density, bone turnover, and upper gastrointestinal tolerability over 2 yr of treatment with alendronate, which produced greater increases from baseline in BMD at 24 months.
Journal ArticleDOI
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
Rieke Alten,Juan J. Gomez-Reino,Patrick Durez,André D. Beaulieu,Anthony Sebba,Gerhard Krammer,R Preiss,Udayasankar Arulmani,A Widmer,Xavier Gitton,Herbert Kellner +10 more
TL;DR: The addition of canakinumab 150 mg SC q4wk improves therapeutic responses among patients who have active RA despite stable treatment with methotrexate, and is associated with significantly more favorable responses at week 12 with respect to secondary endpoints.